Skip to content
Screener

Share Buybacks at other companies

Abbott logo
AbbottABT
$1.05B+17,317%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$0
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
-$7B
Danaher logo
DanaherDHR
$894M
Revvity logo
RevvityRVTY
$86.5M-43.7%
Agilent Technologies logo
Agilent TechnologiesA
$65M-60.6%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$9.3B+30.0%
Enterprise value$9.78B+19.3%
P/E55.1×+32.7×
P/S3.6×+0.8×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000012208-26-000035
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Cash flows from financing activities:
Payments on long-term debt(0.1)(0.1)
Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options3.44.3
Payments for purchases of treasury stock(47.8)(101.9)
Option premium proceeds for structured purchases of treasury stock0.5
Net cash used in financing activities(44.0)(97.7)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash5.9(1.8)
Net increase (decrease) in cash, cash equivalents and restricted cash(23.2)33.3

Item 1. Financial Statements (Unaudited)

FAQ

What is Bio-Rad Laboratories's share buybacks?
Bio-Rad Laboratories (BIO) reported share buybacks of $47.8M in Q1 2026.
How has Bio-Rad Laboratories's share buybacks changed year-over-year?
Bio-Rad Laboratories's share buybacks decreased by 53.1% year-over-year, from $101.9M to $47.8M.
What is the long-term trend for Bio-Rad Laboratories's share buybacks?
Over 3 years (2022 to 2025), Bio-Rad Laboratories's share buybacks has grown at a 11.1% compound annual growth rate (CAGR), from $215.7M to $295.5M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.

Ask your AI about Bio-Rad Laboratories's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude